Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MSH6 |
Variant | E544fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | MSH6 E544fs results in a change in the amino acid sequence of the Msh6 protein beginning at aa 544 of 1360, likely resulting in premature truncation of the functional protein (UniProt.org). E544fs (reported as E544fs*26) has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087), and therefore, is predicted to lead to a loss of Msh6 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
MSH6 mutant MSH6 inact mut MSH6 E544fs |
Transcript | NM_000179.3 |
gDNA | chr2:g.(47799612_47799613) |
cDNA | c.(1630_1629) |
Protein | p.E544fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406812.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406829.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406795.1 | chr2:g.(47799516_47799517) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
XM_024452819.1 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_000179.3 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406798.1 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_000179 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001281493.2 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406815.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_000179.2 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406816.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001281494.2 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001281493.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
XM_024452822.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001281494 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406809.1 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406802.1 | chr2:g.(47799516_47799517) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406808.1 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001281493 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406811.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406800.1 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001281494.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406814.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406823.1 | chr2:g.(47800518_47800519) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406796.1 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
NM_001406803.1 | chr2:g.(47799612_47799613) | c.(1630_1629) | p.E544fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|